AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02250105 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive
Study NCT05890443 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Before starting the research, self-management training in rehabilitation was given to both groups. While the exercise practices were carried out in the experimental group, encouraging reminders were made by following the background web page created in the experimental group.
Study NCT00970879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cotrimoxazole
Description: 800 mg sulfamethoxazole and 160 mg trimethoprim daily, from 28 weeks of gestation until delivery
Study NCT00970879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cotrimoxazole
Description: 800 mg sulfamethoxazole and 160 mg trimethoprim daily, from 28 weeks of gestation until delivery
Study NCT00970879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mefloquine
Description: mefloquine 15 mg/Kg three times, between 16 and 28 weeks, 24 and 32 weeks, then 28 and 36 weeks of pregnancy
Study NCT01389830 — intervention group
Intervention type: BEHAVIORAL
Intervention: Telephone Survey
Description: Telephone interviews (survey) at baseline taking approximately 30-40 minutes to complete; follow-up monthly surveys for cancer patients take 20-30 minutes to complete, follow ups until 12 months or death.
Study NCT03035292 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Red-reflex assessment
Description: The red reflex was examined in the standard manner using direct ophthalmoscope by medical student examiner
Study NCT03035292 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Infrared-reflex assessment
Description: The infrared reflex was examined using a modified smart phone camera by a medical student examiner
Study NCT02611739 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medi-Port
Description: Treatment
Study NCT02611739 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medi-Port
Description: Control
Study NCT01241357 — intervention group
Intervention type: DEVICE
Intervention: Hepatic biomagnetic susceptibility measurement
Description: Subjects will first have an ultrasound study to determine the location of the liver and measure the distance from skin surface to the liver. Subjects will then be examined with the high Tc susceptometer to determine the amount of iron in the liver. The entire procedure will usually take one-half hour or less.
Study NCT02974790 — intervention group
Intervention type: PROCEDURE
Intervention: Echocardiography
Description: Two-dimensional imaging echocardiography
Study NCT02377154 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Slit lamp
Description: Examination of cornea
Study NCT02377154 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Autorefractor
Description: Measurement of refraction
Study NCT02377154 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: IOLMaster 500
Description: Measurement of axial length and white-to-white distance; Keratometry; IOL calculation
Study NCT02377154 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Pentacam HR
Description: Measurement of white-to-white distance; Keratometry
Study NCT02377154 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: LenStar LS900
Description: Measurement of axial length and white-to-white distance; Keratometry; IOL calculation
Study NCT02377154 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: VERION Image Guided System
Description: Measurement of white-to-white distance; Keratometry; IOL calculation with axial length value of IOLMaster 500
Study NCT03638895 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ECAL Indirect Calorimeter
Description: The ECAL is an open-circuit portable indirect calorimeter that measures both volume of CO2 expired and O2 consumed using a small mixing chamber. Participants will breathe through a mouthpiece with a nose clip applied whilst lying in a restful and comfortable position for 15 minutes. ECAL device will provide breath-by-breath measurements of the resting energy expenditure and respiratory quotient which will allow both practitioners and participants to monitor their metabolic health and compare the effect of dietary and physical activity intervention over the course of the structured intensive lifestyle intervention (24-weeks).
Study NCT03638895 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Diet, exercise & behaviour modification therapy
Description: Standard care (SC) - participants receive standard care (diet, exercise \& behaviour modification therapy) as part of the multicomponent weight management intervention within the tier 3 weight management service. Practitioners will rely on standard predictive equations to provide dietary advice and intervention.
Study NCT05759416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin2%gel
Description: Intra-pocket application of 2% Melatonin gel
Study NCT05759416 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: placebo intra-pocket application
Study NCT00868855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bradykinin
Description: Bradykinin, 0.2 ug - 2ug/minute, one time intracoronary infusion over 6 minutes. Drug (bradykinin) will be infused into the left main coronary artery via diagnostic catheter (JL4) at an escalating rate of 0.2, 0.6, 2 g/ml (1ml/min). A 5F Multipurpose catheter will be advanced to coronary sinus for blood sampling.
Study NCT03191487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ChimioPal
Description: Systematic collection of clinical and laboratory toxicities (TXs) during the 2-4 days preceding a chemotherapy (CT) session (48H before a session (D-2 towards the end of the afternoon) and a maximum of 96h before sessions occurring on Mondays (D-4 towards the end of the afternoon). Clinical TX data will be collected via ChimioPal (a self-questionnaire administered by smartphone) and laboratory TX data will be collected via Apicrpyt (secure messaging service) or a fax-to-email service. Data flow management by a nurse dedicated to this activity in each centre will be implemented. If the results of the assessment do not authorize CT, additional assessments may be prescribed. If the experimental data transmission does not occur, the usual pathways will be implemented.~Patient training on how to use a smart phone and the questionnaire will be performed by a nurse before the start of the first chemotherapy session, with reminders at the following sessions if required.
Study NCT01749176 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control-Usual Care
Study NCT01907737 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS
Description: Active tDCS will be applied with the anode positioned over the ipsilesional M1 and the cathode over the contralateral supraorbital region for 20 minutes (1mA).
Study NCT01907737 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Active tDCS
Description: Active tDCS will be applied with the anode positioned over the ipsilesional M1 and the cathode over the contralateral supraorbital region for 20 minutes (1mA).
Study NCT01907737 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active PNS
Description: Active PNS will be administered by 2 pairs of surface electrodes (cathode proximal). One pair will overly the median and ulnar nerves at the wrist, and the other pair will overly the radial nerve. Trains of electric stimulation will be delivered at 1 Hz by using isolation units connected to a square pulse stimulator.
Study NCT01907737 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Active PNS
Description: Active PNS will be administered by 2 pairs of surface electrodes (cathode proximal). One pair will overly the median and ulnar nerves at the wrist, and the other pair will overly the radial nerve. Trains of electric stimulation will be delivered at 1 Hz by using isolation units connected to a square pulse stimulator.
Study NCT01907737 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sham tDCS
Description: In sham tDCS, no current will be delivered through the tDCS device.
Study NCT01907737 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: In sham tDCS, no current will be delivered through the tDCS device.
Study NCT01907737 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sham PNS
Description: No current will be delivered to the radial, ulnar and median nerves.
Study NCT01907737 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham PNS
Description: No current will be delivered to the radial, ulnar and median nerves.
Study NCT00935987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYT387
Description: For the Part 1 dose-escalation portion of the study, patients will be assigned to dose levels in successive cohorts starting with a dose in the first cohort of 100 mg/day. CYT387 will be orally self-administered as a single daily dose beginning on Day 1 of the study, and thereafter at approximately the same time each day of the 28-day cycle. It is recommended that all doses be preceded by a 2-hour fast from food and beverages, and be followed by a 1-hour post-dose fast from food and beverages.~Twenty additional patients will be assigned to a 150 mg BID (twice daily) dosing schedule. CYT387 will be orally self-administered twice-daily with doses approximately 10-12 hours apart beginning on Day 1 of the study, and thereafter at approximately the same times each day of the 28-day cycle.~For the Part 2 dose confirmation portion of the study, patients will be assigned to either 150 mg or 300 mg QD (once daily) dose groups.
Study NCT04664023 — intervention group
Intervention type: PROCEDURE
Intervention: Blood collection at 1st injection of vaccine against COVID-19, at at second injection of vaccine, at Month 1, Month 2, Month 6 and Month 12 after second injection of vaccine for volunteers
Description: 40mL blood sample will be collected at each blood collection for immunologic, enzymatic and metabolic biomarker analysis
Study NCT02493725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eculizumab
Study NCT02493725 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04164888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIVI 007
Description: hypercholesterolemia agent
Study NCT04164888 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CIVI 007
Description: hypercholesterolemia agent
Study NCT04381585 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A MINI DISTRACTOR WITH A SUBMERGED ACTIVATION COMPONENT
Description: Mini distractor is used to regenerate alveolar bone which is resorbed due various reasons. The distractor uses a winch-like submucosal activation component which is buried in the tissue; Flicking the winch turns the screw which moves the segment upwards in the direction of black arrow increasing height.
Study NCT01842984 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-SOCIAL intervention
Description: The I-SOCIAL intervention is based on findings from Cohen-Mansfield and Parpura-Gill (2007), which highlighted the important role of barriers in contributing to loneliness in older persons. These barriers include a perceived lack of opportunities for social contacts, low social self-efficacy, and health and mobility difficulties. The intervention includes: (1) identifying the barriers for the specific person; (2) up to 10 meetings with an activities counselor. The meetings include discussions concerning options for social contacts and use of techniques and resources to tackle the barriers; and (3) group meetings of participants and the activities counselors in order to provide a concrete social event and as a venue to discuss barriers and ways to address them.
Study NCT04163692 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive relaxation exercises
Description: Following intructions have been performed by patients:~* Punch your hands and contract your forearm~* Punch your hands, push your elbow towards the seat~* Bend your elbows~* Push your shoulders back~* Press your knee down and pull your toes towards you~* Pull your knees towards you and push your feet down~* Tighten your hips~* Push your head back~* Lift your eyebrows~* Make wrinkles on your nose~* Tighten your teeth~* Push your chin down~* Close your eyes and think of good things.
Study NCT00519012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline to Paroxetine
Description: For subjects enrolled in this arm, sertraline will be initiated at 25mg, increased to 50mg on day 3, and maintained until day 14. If subjects show an early response (i.e. a 20% improvement in the MADRS total score from baseline) at week 2, sertraline will be continued and titrated at 50 - 100mg based on clinical judgment. On the other hand, if subjects fail to show an early response at week 2, they will be randomly divided into two groups. In one group, sertraline will be continued and titrated at 50 - 100mg, whereas in the other group sertraline will be switched to paroxetine. In this switching group, paroxetine will be started at 10mg on days 15 and 16, increased to 20mg on day 17, and further increased to 40mg by a weekly 10mg increase, while sertraline will be dosed at 25mg on day 15 and terminated on day 16.
Study NCT00519012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine to Sertraline
Description: Paroxetine will be initiated at 10mg, increased to 20mg on day 3, and maintained until day 14. If subjects show an early response (i.e. a 20% improvement in the MADRS total score from baseline) at week 2, paroxetine will be continued and titrated at 20 - 40mg based on clinical judgment. On the other hand, if subjects fail to show an early response at week 2, they will be randomly divided into two groups. In one group, paroxetine will be continued and titrated at 20 - 40mg, whereas in the other group paroxetine will be switched to sertraline. In this switching group, sertraline will be started at 25mg on days 15 and 16, increased to 50mg on day 17, and further increased to 100mg by a weekly 25mg increase, while paroxetine will be dosed at 10mg on day 15 and terminated on day 16.
Study NCT03191487 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual pathways
Description: In the standard arm, the usual management and logistic pathways will be respected. Only extra data collection is required by this study.
Study NCT01454206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iSBIRT
Description: Participants will be screened for substance use, view information about the health effects of substance use on the computer, and receive advice from the primary care provider regarding the health effects of substance use. Those found to be at high risk will complete an internet-based program encouraging them to change their substance use.
Study NCT01944631 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nasal spray saline
Study NCT01944631 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iota-Carrageenan
Description: Nasal spray containing 1.20 g/l Iota-Carrageenan in saline
Study NCT00726206 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electroencephalogram, recording the movements
Description: Electroencephalogram, recording the movements of the child, RMI, Transfontanel Imaging
Study NCT01708330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 2% Lidocaine gel
Study NCT01708330 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: odorless, colorless gel will be used as a placebo
Study NCT02668523 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Raindrop Near Vision Inlay
Description: To improve the near and intermediate vision in subjects who have previously undergone cataract surgery (pseudophakic subjects)
Study NCT01698684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose 15 minutes before attempting intercourse
Study NCT01698684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avanafil 100 mg
Description: One dose 15 minutes before attempting intercourse
Study NCT01698684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avanafil 200 mg
Description: One dose 15 minutes before attempting intercourse
Study NCT02539810 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal artery Angioplasty plus stenting.
Description: renal artery stenting
Study NCT02155218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gadolinium contrast
Study NCT02155218 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: gadolinium contrast
Study NCT02653001 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stool sample collection
Description: Collection of complete stool sample
Study NCT02539810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti hypertensive, statin and antiplatelet medication.
Description: Slow release indapamide 1.5 mg/d (or furosemide 40 mg/d if eGFR is \< 30 mL/min/1.73m²) + irbesartan 300 mg/d + amlodipine 10 mg/d + aspirin 75 mg/d (or clopidogrel 75 mg/d in case of allergy or gastrointestinal intolerance to aspirin) + atorvastatin 20 mg/d. After randomization, bisoprolol 10 mg/d, prazosin 5 mg/d, and rilmenidine 1 mg/d and spironolactone 12.5 to 25 mg/d, will be sequentially added from months two to five in both groups if home blood pressure remains more than or equal to 135/85 mm Hg.
Study NCT02539810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti hypertensive, statin and antiplatelet medication.
Description: Slow release indapamide 1.5 mg/d (or furosemide 40 mg/d if eGFR is \< 30 mL/min/1.73m²) + irbesartan 300 mg/d + amlodipine 10 mg/d + aspirin 75 mg/d (or clopidogrel 75 mg/d in case of allergy or gastrointestinal intolerance to aspirin) + atorvastatin 20 mg/d. After randomization, bisoprolol 10 mg/d, prazosin 5 mg/d, and rilmenidine 1 mg/d and spironolactone 12.5 to 25 mg/d, will be sequentially added from months two to five in both groups if home blood pressure remains more than or equal to 135/85 mm Hg.
Study NCT02184611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umeclidinium bromide
Description: Blended with lactose and magnesium stearate dry white powder of umeclidinium 62.5 mcg to be inhaled via a NDPI
Study NCT02184611 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Blended with lactose and magnesium stearate dry white powder to be inhaled via a NDPI
Study NCT03530930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comarum Palustre
Description: Comarum Palustre tablets 500 mg BID, 1 month
Study NCT02940366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg orally daily
Description: Pitavastatin 4 mg orally daily for 24months
Study NCT02940366 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin 20 mg orally daily
Description: Atorvastatin 20 mg orally daily for 24months
Study NCT04375748 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Performing routine care (clinical and paraclinical tests)
Description: ECG, standard biology and cardiology tests, and routine transthoracic echocardiography (TTE), MRI
Study NCT04375748 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Examinations for the research:
Description: Systematic research by polymerase chain reaction (PCR) for Covid-19 in the blood and in an oro-pharyngeal swab, in addition to the usual immunologic, bacteriological, viral and parasitic tests carried out as part of the routine care of all patients with suspected myocarditis.~A 30-days phone call follow-up (vital status) and a systematic 1-year follow-up will be realized (clinic, biology, ECG, TTE, +/- MRI)
Study NCT03509649 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical spine manipulation
Description: High-velocity low-amplitude thrust joint manipulation to the cervical spine
Study NCT03509649 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical spine manipulation
Description: High-velocity low-amplitude thrust joint manipulation to the cervical spine
Study NCT01666951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCP-Tacro tablets
Description: Tacrolimus
Study NCT01666951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: Tacrolimus
Study NCT02672787 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ED-based behavioral intervention
Description: Data collection, antihypertensive adherence assay, antihypertensive interview and EHR review, barrier identification, personalized goal setting, communication with PCP, and reminder messages/engagement messages.
Study NCT02672787 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ED usual care plus education
Description: Data collection, antihypertensive adherence assay, antihypertensive interview, EHR review, and usual care education.
Study NCT04455789 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: routine lung protective, conventional mechanical ventilation
Description: routine lung protective, conventional mechanical ventilation with stabil PEEP
Study NCT01808950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.06% Resiquimod Gel - A
Description: single 60mg dose
Study NCT01808950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.06% Resiquimod Gel - B
Description: single 100mg dose
Study NCT01808950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.06% Resiquimod Gel - C
Description: shave biopsy of BCC followed by single 100mg dose
Study NCT05189808 — intervention group
Intervention type: PROCEDURE
Intervention: Radiofrequency Ablation
Description: Ultrasound guided radiofrequency ablation (non-experimental)
Study NCT00922285 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychosocial support for caregiver
Description: 6 weekly 60 minute sessions
Study NCT00922285 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Evaluated at baseline, week 1 and week 6 of art therapy